CAS: 212631-79-3; 2-((2-Chloro-4-Iodophenyl)Amino)-N-(Cyclopropylmethoxy)-3,4-Difluorobenzamide

该化合物是一种合成有机化合物,其特征是复杂的分子结构,包括多种功能组;该化合物的特征是苯丙胺核心,代之以苯环上的一个氯和碘基,有助于其潜在的生物活动;环丙基丙基乙酰胺组的存在,增强了其亲脂性,有可能影响其药用植物特性;此外,二氟苯丙胺混合物的特性可能具有独特的电子特征,影响其再活动性和与生物目标的相互作用;该化合物可能呈现出特定的溶性和稳定性特征,受到其卤素亚组成部分和环丙基化合物组的影响;这些结构特征表明,它可能对医药化学感兴趣,特别是针对特定途径或疾病的药品的研发感兴趣;然而,需要进行详细研究,以充分阐明其特性,包括其生物活动,毒性和潜在用途.

结构式图片

欧盟法规

C&L通报

上下游产品

3,4-difluoro-2-(2-chloro-4-iodophenylamino)-benzoic acid benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 2-chloro-4-iodoaniline 2,3,4,-trifluorobenzoic acid

合成工艺路线路线简述

    2,3,4-三氟苯甲酸置于n,N'-二环己基碳二亚胺,Lithium Diisopropyl Amide体系中,用 四氢呋喃,正庚烷,乙基苯,N,N-二甲基甲酰胺 用作溶剂,化学反应 146.0H,反应生成4-辛基酚乙氧基化物
    参考文献:Improved Experimental Procedure For The Synthesis Of The Potent Mek Inhibitor Pd184352
    标题:Improved Experimental Procedure For The Synthesis Of The Potent Mek Inhibitor Pd184352
    摘要:An Improved Synthesis Of The Potent Mek Inhibitor Pd184352 (2-(2-Chloro-4-Iodo-Phenylamino)-N-Cyclopropylmethoxy-3,4-Difluoro-Benzamide)) Is Herein Reported. This New And Reproducible Protocol Provides A Simple And Efficient Way Of Generating Gram Quantities Of Pd 184352 With Minimal Purification.
    Doi:10.1080/00397910500184909

    海关参考信息

    专利信息


    专利号:US-2025206743-A1
    优先权日:2022-03-25
    标 题:Tyk2 inhibitor synthesis and intermediates thereof
    发明人:MASSE CRAIG E; PHADKE AVINASH S; LAWSON JON P; LEVY STUART; YANG XIAOWEI; WU GUISHENG; FAN SHUFENG
    权利人:TAKEDA PHARMACEUTICALS CO
    摘要:Described herein are methods of synthesis of a tyrosine-protein kinase 2 (TYK2) inhibitor and to intermediate compounds of the synthesis and methods of making the intermediates. Also provided are pharmaceutically acceptable compositions including compounds prepared by the synthetic method and methods of treating disorders using the same.

    专利号:US-2025289827-A1
    优先权日:2022-12-02
    标 题:Morphic forms of a mutant braf degrader and methods of manufacture thereof
    发明人:YU ROBERT T; HE MINSHENG; SCHNADERBECK MATTHEW J; KREGER BRIDGET; POLLOCK ROY MACFARLANE; JIANG SIYI; LI MEIQI; CHEN BOLU; LU JIANNAN
    权利人:C4 THERAPEUTICS INC
    摘要:Advantageous isolated morphic forms of (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane (Compound 1), which is a mutant BRAF degrader, and methods to prepare Compound 1 morphic forms for therapeutic applications are provided in the invention. The invention also provides improved methods for the synthesis of Compound 1, new pharmaceutical compositions comprising Compound 1, and new uses of Compound 1.

    专利号:US-9365532-B1
    优先权日:2011-02-14
    标题:Synthesis, composition and use of novel therapeutic and cosmetic Schiff base products formed by reaction of a carbonyl containing moeity with a transimination nucleophilic catalyst and the use of transimination nucleophilic catalysts to increase the rate at which carbonyl containing therapeutic and cosmetic actives form Schiff base products with biological amines
    发明人:ISAACMAN STEVEN
    权利人:ISAACMAN STEVEN; NANOMETICS LLC
    摘要:The present invention relates to the synthesis, composition and use of novel moieties formed by reacting a transimination nucleophilic catalyst, molecular or polymeric, with carbonyl-containing therapeutic or cosmetic moieties. The resultant Schiff base product is highly reactive towards transimination with a biological amine. The catalyst and carbonyl-containing moiety can be molecular or polymeric, and the resultant chemical and physical properties of the Schiff base products can be engineered by appropriate selection of said catalyst. The present invention also relates to the synthesis, composition and use of novel moieties that are used as actives in sunless tanning preparations. The present invention also relates to the use of transimination nucleophilic catalysts to increase the rate at which a carbonyl-containing moiety reacts with a biological amine. The present invention also relates to the use of transimination nucleophilic catalysts to increase the rate and efficacy of commercial sunless tanning preparations. Improvements on stability and efficacy of said preparations are disclosed. While the invention has been described in terms of its preferred embodiments, those skilled in the art will recognize that the invention can be practiced with modification within the spirit and scope of the appended claims. Accordingly, the present invention should not be limited to the embodiments as described above, but should further include all modifications and equivalents thereof within the spirit and scope of the description provided herein.

    专利号:US-2019031650-A1
    优先权日:2016-01-29
    标 题 :Dna alkylation and cross-linking agents as compounds and payloads for targeted therapies
    发明人:HERZON SETH; HEALY ALAN; CRAWFORD JASON; VIZCAINO MARIA; NIKOLAYEVSKIY HERMAN
    权利人:UNIV YALE
    摘要:The present invention is directed to compounds related to precolibactin pharmaceutical compositions based upon these compounds and methods of synthesis which are employed to provide intermediates and final compounds, which are principally alkylating agents and anticancer compounds. The chemical synthetic approach disclosed facilitates the synthesis of numerous precolibactin analogs which can be used in the treatment of cancer.

    专利号:US-2022143183-A1
    优先权日:2019-02-23
    标题:Photoswitchable protacs and synthesis and uses thereof
    发明人:TRAUNER DIRK; REYNDERS MARTIN; MATSUURA BRYAN; BEROUTI MARLEEN; PAGANO MICHELE
    权利人:UNIV NEW YORK
    摘要:Provided are compounds, which may be referred to as PHOTACs (photoswitchable proteolysis targeting chimeras), and compositions, kits, and methods of making and using PHOTACs. PHOTACs have one or more E3 ligase ligand(s), one or more photoswitchable group(s), optionally, one or more linker(s), and one or more ligand(s) for a target protein. PHOTACs may be suitable for use in methods to treat diseases, such as, for example, cancer. PHOTACs may also be suitable for use in methods to induce selective degradation of a target protein.

    专利号:CN-118922420-A
    优先权日:2022-03-25
    标题 :Synthesis of TYK2 inhibitors and their intermediates
    上海泽涵生物医药科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.zehanbiopharma.com
    电话: 021-61350663 13052117465👤
    📞上海泽涵生物医药科技有限公司 ⚠️参考联系方式

    销售电话:021-61350663 13052117465
    邮箱:sales@zehanbiopharma.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, Wang DS, Lu YS, Hsu C, Cheng AL. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma. Clin Cancer Res. 2009 Sep 15;15(18):5820-8. Epub 2009 Sep 8. Epub 2008 Oct 15. Epub 2007 Oct 2. Epub 2005 Oct 20. Epub 2005 Jul 11.
    10: McDaid HM, Lopez-Barcons L, Grossman A, Lia M, Keller S, Pérez-Soler R, Horwitz SB. Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res. 2005 Apr 1;65(7):2854-60.

    合成参考文献


    参考文献:10.4161/cbt.4.11.2286
    摘要:Hawkins W, Mitchell C, McKinstry R, Gilfor D, Starkey J, Dai Y, Dawson K, Ramakrishnan V, Roberts JD, Yacoub A, Grant S, Dent P. Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Cancer Biol Ther. 2005 Nov;4(11):1275–84. doi: 10.4161/cbt.4.11.2286.
    参考文献:10.1186/1471-2202-12-69
    摘要:Hughes R, Gilley J, Kristiansen M, Ham J. The MEK-ERK pathway negatively regulates bim expression through the 3' UTR in sympathetic neurons. BMC Neuroscience. 2011 Jul 15;12(1):69. doi: 10.1186/1471-2202-12-69.
    参考文献:10.4161/cbt.4.11.2335
    摘要:Franklin RA, Libra M, Stivala F, McCubrey JA. Two targets are better than one. Promising combination therapy to treat breast cancer. Cancer Biol Ther. 2005 Nov;4(11):1190–1. doi: 10.4161/cbt.4.11.2335.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知